Clover Biopharmaceuticals’ Covid-19 protein subunit vaccine could potentially have the upper hand versus Novavax’s and IMV’s due to the former’s use of Dynavax Technologies’ FDA-approved adjuvant. However, it is premature to predict a clear frontrunner among the three vaccines due to information gaps such as how the spike protein antigen is constructed and reproduction platforms to be used for manufacturing. ClinicalTrialsArena
Thursday, May 28, 2020
Clover’s adjuvant choice for Covid-19 an edge, but comparison with IMV’s, Novavax’s vaccines limited
Clover Biopharmaceuticals’ Covid-19 protein subunit vaccine could potentially have the upper hand versus Novavax’s and IMV’s due to the former’s use of Dynavax Technologies’ FDA-approved adjuvant. However, it is premature to predict a clear frontrunner among the three vaccines due to information gaps such as how the spike protein antigen is constructed and reproduction platforms to be used for manufacturing. ClinicalTrialsArena
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment